M&A Deal Summary

Tourmaline Bio Acquires Tourmaline Bio

On June 22, 2023, Tourmaline Bio acquired life science company Tourmaline Bio

Acquisition Highlights
  • This is Tourmaline Bio’s 1st transaction in the Life Science sector.
  • This is Tourmaline Bio’s 1st transaction in the United States.
  • This is Tourmaline Bio’s 1st transaction in New York.

M&A Deal Summary
Date 2023-06-22
Target Tourmaline Bio
Sector Life Science
Buyer(s) Tourmaline Bio
Deal Type Merger
Advisor(s) Jefferies
Piper Sandler & Co.
Guggenheim Securities
Truist Securities (Financial)
Cooley (Legal)

Target

Tourmaline Bio

New York, New York, United States
Tourmaline Bio is a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune diseases. Tourmaline Bio is based in New York.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Tourmaline Bio

New York, New York, United States
Category Company
Sector Life Science
Employees44
Revenue 45M USD (2023)
DESCRIPTION

Tourmaline Bio is a late-clinical stage biotechnology company that is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. Tourmaline Bio is based in New York, New York.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Merger) 1 of 1
State (New York) 1 of 1
Country (United States) 1 of 1
Year (2023) 1 of 1
Mergr

Product

Company

Legal